Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RGL-305 in Patients With Lymphoma
NCT07006012Phase 1Recruiting
- Sponsor
- Fudan University
- Start
- Apr 2025
- Primary completion
- Mar 2028
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of RGL-305 in lymphoma (2 arms), sponsored by Fudan University. Primary endpoint: Safety and tolerability of RGL-305 up to 2 years. Started Apr 2025; status: recruiting.
02
Drugs
RGL-305
03
Conditions
lymphoma
Beyond the preview
Go deeper on NCT07006012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006012.